Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 4/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | MAPKAPK5 | Q8IW41 | 5/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25447053 | 0.88 | TTK (0.54) | TTKAURKAFYNMAPKAPK5SRC | |
| SCHEMBL25447222 | 0.84 | TTK (0.57) | TTKAURKAFYNMAPKAPK5SRC | |
| SCHEMBL25447058 | 0.83 | TTK (0.57) | TTKAURKAFYNMAPKAPK5SRC | |
| SCHEMBL3466981 | 0.81 | SRC (0.56) | TTKAURKAFYNMAPKAPK5SRC | |
| SCHEMBL12409302 | 0.79 | TTK (0.66) | TTKBRAFAURKAFYNMAPKAPK5 | |
| SCHEMBL14767444 | 0.79 | TTK (0.54) | TTKBRAFAURKAFYNMAPKAPK5 | |
| SCHEMBL25444178 | 0.78 | PTK6 (0.42) | TTKAURKAFYNMAPKAPK5AURKB | |
| SCHEMBL14536959 | 0.76 | TTK (0.54) | TTKAURKAFYNMAPKAPK5SRC | |
| SCHEMBL5411598 | 0.76 | TTK (0.68) | TTKFLT3 | |
| SCHEMBL3471147 | 0.76 | MAPK1 (0.56) | TTKBRAFAURKAFYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | TTK 4157/4885BRAF 1177/4885AURKA 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.